Primary Job Title CEO Primary Organization Plopii
Location Los Angeles, California, United States Regions Greater Los Angeles Area, West Coast, Western US Gender Male
Website plopii.com Facebook View on Facebook LinkedIn View on LinkedIn X (Twitter) View on X
Michael Tolmach is Co-Founder and CEO of Plopii LLC, a next generation energy platform company developing patented formulations across cognitive enhancement, analgesic optimization, and performance energy powered by paraxanthine. Tolmach is first-named inventor on three U.S. utility patent applications filed in 2026: U.S. App. No. 19/630,373
covering the Plopii Pouches nootropic oral pouch with Tripartite Cholinergic Enhancement architecture, filed March 26, 2026; U.S. App. No. 19/636,926 covering paraxanthine as a universal adjuvant analgesic enhancer combined with acetaminophen, aspirin, ibuprofen, or naproxen, filed April 1, 2026; and U.S. App. No. 19/641,518 covering the Plopii Energy paraxanthine-anchored nootropic energy drink with dual cholinergic stack and carbonation-stable probiotic, filed April 8, 2026. The combined portfolio spans 64 or more claims across a total addressable market of approximately 146.5 billion dollars globally.
Prior to Plopii, Tolmach co-founded Eonsmoke LLC, one of the leading U.S. vaping brands of its era, scaling from 2.3 million dollars in revenue in 2017 to 90 million dollars in 2019 on approximately 1.25 million dollars in total capital raised. Eonsmoke was covered by the Wall Street Journal, Bloomberg Law, CNN, and the New York Post. He also co-founded Purpyle, a direct-to-consumer eyewear brand, and Glidecraft LLC, a personal electric mobility company. He holds Series 3, 7, and 63 securities licenses and attended Bronx High School of Science and Baruch College at the City University of New York. He is based in Los Angeles, California.
